Naive CD4+T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ROR1-CAR T Cells

被引：0

作者：

Hudecek, Michael ^{[1
]}

Lupo-Stanghellini, Maria-Teresa ^{[1
]}

Kosasih, Paula ^{[1
]}

Bet, Jeannette ^{[1
]}

Paszkiewicz, Paulina ^{[1
]}

Maloney, David G. ^{[1
]}

Jensen, Michael C. ^{[2
]}

Rader, Christoph ^{[3
]}

Riddell, Stanley R. ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

[2] Seattle Childrens Res Inst, Ctr Childhood Canc Res, Seattle, WA USA

[3] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：294 / 294

页数：1

共 50 条

[31] Preclinical evaluation of anti-ROR1 CAR T cells employing a ROR1 binding SCFV derived from the clinical stage mab cirmtuzumab
Prussak, Charles E.
Oh, Christopher
Lujan, Juliana Velez
Lam, Sharon
Zhang, Jieyu
Fernandez, Jayde
Sinha, Navyaa
Pham, Jessica
Shi, Haoming
Shin, Caitlin
Kaufman, Gunnar F.
Widhopf, George F., II
Cohen, Ezra E. W.
Kipps, Thomas J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
[32] Differential modulation of the PD-1 pathway impacts the anti-tumor activity of CAR T cells
Lin, Regina J.
Gautron, Anne-Sophie
Poirot, Laurent
Wong, Oi Kwan
Sasu, Barbra
Boldajipour, Bijan
CANCER RESEARCH, 2017, 77
[33] Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Hudecek, Michael
Lupo-Stanghellini, Maria-Teresa
Kosasih, Paula L.
Sommermeyer, Daniel
Jensen, Michael C.
Rader, Christoph
Riddell, Stanley R.
CLINICAL CANCER RESEARCH, 2013, 19 (12) : 3153 - 3164
[34] CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells
Yang, Yinmeng
Lin, Tasha
Jacoby, Elad
Qin, Haiying
Gardner, Elizabeth Grier
Chien, Christopher Daniel
Lee, Daniel W., III
Fry, Terry J.
BLOOD, 2015, 126 (23)
[35] The anti-tumor function of ROR1-CAR modified T-cells against triple-negative breast cancer is enhanced by shielding from immunosuppressive TGF-β
Stueber, T.
Wallstabe, L.
Rydzek, J.
Nerreter, T.
Woeckel, A.
Einsele, H.
Wischhusen, J.
Hudecek, M.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 7 - 7
[36] Unedited CD7 CAR T-Cells Overcome Fratricide and Produce Superior Anti-Tumor Activity in a Preclinical Model of T-Cell Leukemia
Watanabe, Norihiro
Mo, Feiyan
Ma, Royce
Srinivasan, Madhuwanti
McKenna, Mary K.
Scherer, Lauren D.
Mamonkin, Maksim
MOLECULAR THERAPY, 2021, 29 (04) : 302 - 303
[37] Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
Stuber, Tanja
Monjezi, Razieh
Wallstabe, Lars
Kuehnemundt, Johanna
Nietzer, Sarah Louise
Dandekar, Gudrun
Woeckel, Achim
Einsele, Hermann
Wischhusen, Joerg
Hudecek, Michael
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[38] Ocular melanoma cells genetically modified to express HLA-DR and CD80 activate tumor-specific CD4+T cells
Bosch, Jacobus J.
Thompson, James A.
Dissanayake, Samudra K.
Ksander, Bruce R.
Ostrand-Rosenberg, Suzanne
JOURNAL OF IMMUNOLOGY, 2006, 176 : S258 - S258
[39] Unhelpful CD4 help: Removal of conventional CD4+T cells promotes priming of tumor antigen-specific CD8 T cells in the context of CD4-depletion therapy
Dragnev, Christo P. C.
Ramirez, Delaney E.
Searles, Tyler G.
Spicer, Nathaniel
Chen, TIffany
Lines, J. Louise
Hawkes, Aaron R.
Davis, Wilson L., III
Mohamed, Asmaa
Shirai, Keisuke
Phillips, Joesph D.
Rosato, Pamela C.
Huang, Yina H.
Turk, Mary Jo
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
[40] MALT1-induced Roquin cleavage in T cells and CAR T cells is critical for anti-tumor immunity
Negraschusl, Arlinda
Holtermann, Anne
Edelmann, Stephanie
Rupp, Luise
Fuechsl, Franziska
Krackhardt, Angela
Schmitz, Marc
Kobold, Sebastian
Heissmeyer, Vigo
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 340 - 340

← 1 2 3 4 5 →